English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose of the study The benefit of newer antiretroviral regimens on clinical end-points for treatment-experienced, HIV-1-infected patients remains to be determined. Etravirine (ETR) demonstrated durable efficacy and safety in HIV-1 infected, treatment-experienced patients in the phase III DUET trials. We report adjudicated clinical end-points from a prespecified pooled analysis of DUET-1 and DUET-2 after 48 weeks of treatment.

Reduction in AIDS defining events/deaths with etravirine (ETR; TMC125) compared to placebo: pooled DUET 48-week results